Introduction
============

Liver cancer ranked in the top 10 among estimated new cases of cancer and associated worldwide in 2018, across 20 world regions, with 841,080 (4.7%) new cases and 781,631 (8.2%) mortalities ([@b1-ijo-55-04-0860]). Hepatocellular carcinoma (HCC) is not only the predominant histological type of liver cancer, but also accounts for the highest proportion of \~80% of all primary liver cancer incidences ([@b2-ijo-55-04-0860]). In China, HCC is a common type of tumor and is the second leading cause of cancer mortality ([@b3-ijo-55-04-0860]). Approximately 80-90% of all HCC cases are a result of liver cirrhosis, while the second highest percentage is a result of persistent hepatitis B or C virus (HBV) infection ([@b4-ijo-55-04-0860]). Other risk factors for HCC include obesity, iron overload, alcohol abuse, environmental pollutants and aflatoxin contaminations ([@b5-ijo-55-04-0860],[@b6-ijo-55-04-0860]). Early-stage HCC can be diagnosed and effectively treated through curative resection and liver transplantation, but treatments for advanced HCC are limited and have unsatisfactory outcomes ([@b7-ijo-55-04-0860],[@b8-ijo-55-04-0860]). HCC tumor recurrence, drug resistance, and disease relapse after therapy are critical issues that result in poor prognosis ([@b8-ijo-55-04-0860],[@b9-ijo-55-04-0860]).

Long noncoding RNAs (lncRNAs), of \>200 nucleotides in length, are a subclass of functional noncoding RNAs that are capable affecting protein expression ([@b10-ijo-55-04-0860],[@b11-ijo-55-04-0860]). These lncRNAs share several characteristics of mRNAs: LncRNAs are 5′capped, equipped with a 3′polyadenylate tail, are made up of a variety of exons and are transcribed by RNA polymerase II ([@b11-ijo-55-04-0860],[@b12-ijo-55-04-0860]). Previous studies have indicated that lncRNAs play a pivotal role in many biological processes, including cell cycle regulation, cardiac development and X chromosome inactivation ([@b11-ijo-55-04-0860]-[@b14-ijo-55-04-0860]). In addition, lncRNAs are involved in several diseases ([@b15-ijo-55-04-0860]). Microarray technology has identified both upregulated and downregulated lncRNAs in a large number of malignancies, such as breast cancer ([@b16-ijo-55-04-0860]), prostate cancer ([@b17-ijo-55-04-0860]), lung cancer ([@b18-ijo-55-04-0860]) and HCC ([@b19-ijo-55-04-0860]).

LncRNA LINC00668 has been identified to be associated with tumor progression and prognosis: LINC00668, along with LINC00710 and LINC00607, are the three most significantly downregulated lncRNAs in lung adenocarcinoma ([@b20-ijo-55-04-0860]). LINC00668 has been identified as a potentially carcinogenic lncRNA and its knockdown can inhibit the proliferation, invasion and migration abilities of laryngeal squamous cell carcinoma (LSCC) cell lines ([@b21-ijo-55-04-0860]). Induced by E2F transcription factor 1, upregulated LINC00668 can predict poor prognosis of gastric cancer (GC) and promote cell proliferation by epigenetically silencing cyclin-dependent protein kinase inhibitors ([@b22-ijo-55-04-0860]). However, the aforementioned studies did not report the tissues specificities of LINC00668 in tumor cells. Databases (<https://portals.broadinstitute.org/ccle/page?gene=LINC00668>) indicate that tumor cells of these organs expressing LINC00668 highly are meningioma, colorectal, stomach, bile duct and liver. In addition, the association between LINC00668 and HCC remains unclear. Therefore, we conducted an analysis to explore the potential roles of LINC00668 in HCC diagnosis, prognosis and its molecular mechanism.

Materials and methods
=====================

Data source and genome-wide co-expression correlated genes
----------------------------------------------------------

Clinical data and the gene expressions of HCC patients were obtained from The Cancer Genome Atlas (TCGA; <https://cancergenome.nih.gov/>). The treatments of these patients underwent can be accessed at <https://xenabrowser.net/datapages/?host=https%3A%2F%2Ftcga.xenahubs.net&removeHub=https%3A%2F%2Fxena.treehouse.gi.ucsc.edu%3A443>. The co-expression correlation coefficient was used to evaluate the correlation between LINC00668 and genome-wide genes, using R 3.5.0 (<https://www.r-project.org/>). LncRNAs do not encode proteins alone, and their function has been associated with co-expressed protein coding genes (PCGs) ([@b23-ijo-55-04-0860],[@b24-ijo-55-04-0860]). LINC00668 and its top 10 correlated genes, known as PCGs, were employed for further analysis based on the median levels of expression which served as the cut-off value; they were further divided as low and high expression PCGs.

Expression of LINC00668 and genes in tumor and non-tumor tissue
---------------------------------------------------------------

The expression of LINC00668 and its top 10 PCGs in tumor and non-tumor tissues were obtained from the Metabolic gEne RApid Visualizer (<http://merav.wi.mit.edu/>) ([@b25-ijo-55-04-0860]). Scatter plots were then created in TCGA database using these data and were visualized using GraphPad 7.0 (GraphPad Software, Inc.).

Diagnostic, prognostic and joint-effect analysis of LINC00668 and its PCGs
--------------------------------------------------------------------------

The diagnostic value of LINC00668 and its top 10 PCGs were visualized in GraphPad 7.0, using receiver operating characteristic (ROC) curves. An area under curve (AUC) value of \<0.7 was considered significant for HCC diagnosis. Then, joint-effect analysis was performed between significant genes and LINC0068.

Thereafter, their prognostic value for overall survival (OS) were analyzed using SPSS 16.0 (SPSS, Inc.) and the results were presented using Kaplan-Meier plots visualized using GraphPad 7.0. Joint-effect analysis with LINC00668 was performed on genes that were of prognostic significance for HCC.

Gene set enrichment analysis (GSEA)
-----------------------------------

GSEA (<http://software.broadinstitute.org/gsea/index.jsp>.), which includes Gene Ontology (GO): Biological process (BP), cellular component (CC), molecular function (MF) and Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic pathway analyses, was performed to explore the potential molecular mechanisms of LINC00668 and genes that are responsible for the development and progression of HCC. Then, the KEGG set (c2.cp.kegg. v6.1.symbols.gmt) and GO sets (c5.bp.v6.1.symbols.gmt, c5.cc. v6.1.symbols.gmt, c5.mf.v6.1.symbols.gmt) obtained were used for analysis.

Nomogram, co-expression matrix, gene-gene interaction (GGI) and GO interaction network
--------------------------------------------------------------------------------------

Prognosis-related genes, LINC00668 and clinical factors were included in the nomogram. The nomogram was constructed and used for 1 year, 3 year, and 5 year OS prediction. Afterwards, the co-expression matrix between top 10 genes and LINC00668 was constructed using R 3.5.0 software. The interaction network between the genes and LINC00668 was presented using the geneMANIA plugin of Cytoscape software ([@b26-ijo-55-04-0860],[@b27-ijo-55-04-0860]). Moreover, GO terms were visualized using the BinGO plugin of Cytoscape software ([@b28-ijo-55-04-0860]).

Pharmacological targets and drug selection
------------------------------------------

Genome-wide differentially expressed genes (DEGs), including upregulated and downregulated genes, as well as heatmaps and volcano plots were obtained using edgeR ([@b29-ijo-55-04-0860]). The results with a fold change of \>2 and P≤0.05 were used for further analysis. Then, target drugs were selected from the Connectivity Map (<https://portals.broadinstitute.org/cmap/>). The chemical composition of these drugs were acquired from PubChem Compound (<https://www.ncbi.nlm.nih.gov/pccompound/>). GO terms were visualized based on the DEGs using BinGO. Then, enrichment analysis was performed based on the DEGs using the Database for Annotation, Visualization and Integrated Discovery v6.8 (DAVID; <https://david.ncifcrf.gov/>) ([@b30-ijo-55-04-0860],[@b31-ijo-55-04-0860]).

Statistical analysis
--------------------

Survival analyses was performed using SPSS 16.0 software. Median survival time, log-rank P-values, 95% confidence intervals (CI) and hazard ratios (HR) were calculated using the Kaplan-Meier method and Cox proportional hazards regression models. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Co-expression of correlated genome-wide genes and clinicopathological characteristics of HCC patients
-----------------------------------------------------------------------------------------------------

Co-expression of correlated genome-wide genes with LINC00668 were calculated and are shown in [Table SI](#SD2-ijo-55-04-0860){ref-type="supplementary-material"}. The top 10 PCGs of LINC00668 were pyrimidineregic receptor P2Y4 (*P2RY4*), signal peptidase complex subunit 2 (*SPCS2*), family with sequence similarity 86 member C1 (*FAM86C1*), tudor domain containing 5 (*TDRD5*), ferritin light chain (*FTL*), stratifin (*SFN*), nucleolar complex associated 2 homolog (*NOC2L*), peroxiredoxin 1 (*PRDX1*), cancer/testis antigen 2 (*CTAG2*) and leucine zipper and CTNNBIP1 domain containing (*LZIC*) ([Table I](#tI-ijo-55-04-0860){ref-type="table"}). Then, LINC00668 and the top 10 PCGs were further explored for their diagnostic, prognostic significance, along with their molecular mechanisms in HCC. A total of 370 HCC patients were enrolled in the analysis. HBV status, tumor stage and radical resection status were found to be associated with OS (log-rank P\<0.0001, P\<0.0001, P 0.007, respectively; [Table II](#tII-ijo-55-04-0860){ref-type="table"}).

Expression of LINC00668 and PCGs in tumor and non-tumor tissues
---------------------------------------------------------------

LINC00668, *P2RY4* and *CTAG2* exhibited high expression in non-tumor tissues, whereas other PCGs showed low expression levels in non-tumor tissues ([Fig. 1](#f1-ijo-55-04-0860){ref-type="fig"}). TCGA indicated that the expression of LINC00668, *FAM86C1*, *SFN*, *NOC2L*, *PRDX1* and *CTAG2* were significantly different between tumor and non-tumor tissues (P\<0.05; [Fig. 2](#f2-ijo-55-04-0860){ref-type="fig"}). Moreover, all the PCGs that were significantly differentially expressed were upregulated in tumor tissues.

Diagnostic, prognostic and joint-effect Analysis of LINC00668 and PCGs
----------------------------------------------------------------------

In the diagnostic analysis, FAM86C1, CTAG2 and SFN were found to be significant for the diagnosis of HCC ([Fig. 3D, J and G](#f3-ijo-55-04-0860){ref-type="fig"}, AUC=0.766, 0.725 and 0.820; P\<0.0001, respectively), while LINC00668, P2RY4, and SPCS2 were found to be of weak diagnostic significance ([Fig. 3A-C](#f3-ijo-55-04-0860){ref-type="fig"}, AUC= 0.666, 0.640, and 0.614; P\<0.001, P= 0.001, P= 0.009, respectively). Other PCGs, TDRD5, FTL, NOC2L, PRDX1 and LZIC, did not show any significance for the diagnosis of HCC ([Fig. 3E-F, H-I, K](#f3-ijo-55-04-0860){ref-type="fig"}, all AUCs\<0.600). Then, joint-effect analysis was performed on LINC00668 and the significant PCGs ([Fig. 4](#f4-ijo-55-04-0860){ref-type="fig"}). Joint-effect analysis demonstrated that all of these have a larger AUC value than each alone.

For the prognostic analysis, LINC00668, *FAM86C1, TDRD5*, *FTL* and *SFN* exhibited prognostic significance in the multivariate analysis ([Table III](#tIII-ijo-55-04-0860){ref-type="table"}, adjusted P=0.029, 0.003, 0.012, 0.042 and 0.005, respectively), while LINC00668, *FAM86C1, TDRD5*, and *SFN* exhibited prognostic significance in the univariate analysis ([Table III](#tIII-ijo-55-04-0860){ref-type="table"}, [Fig. 5](#f5-ijo-55-04-0860){ref-type="fig"}, P=0.025, 0.001, 0.007, 0.003, respectively). Then, joint-effect analysis was performed on LINC00668 and the significant PCGs ([Table IV](#tIV-ijo-55-04-0860){ref-type="table"}, [Fig. 6](#f6-ijo-55-04-0860){ref-type="fig"}). The groups with low expression in both analyses exhibited the most significance for prognosis; and groups with high expression in both analyses presented as the poorest indicators of prognosis; while groups with both low and high expressions are set in the middle.

GSEA
----

GSEA was conducted to explore the genome-wide potential molecular mechanisms of LINC00668 and its PCGs. The GSEA of LINC00668 indicated that it is involved in \'cell division\', \'mitotic nuclear division\', \'sister chromatid segregation\', cell cycle phase transition, \'cell cycle G2 M phase transition\', \'spindle\', \'chromosome centromeric region\', \'DNA dependent ATPase activity\', \'chromatin binding\', \'drug metabolism cytochrome P450\', and \'fatty acid metabolism\' ([Fig. 7](#f7-ijo-55-04-0860){ref-type="fig"}). The GSEA of *FAM86C1* indicated that it is involved in \'ncRNA processing\', \'RNA modification\', \'RNA catabolic process\', \'ncRNA metabolic process\', \'ribosome biogenesis\', \'ribosomal small subunit biogenesis\', \'preribosome\', \'ribosomal subunit\', \'RRNA binding\', \'ribosome\', \'oxidative phosphorylation\' and \'Alzheimer\'s disease\' ([Fig. 8](#f8-ijo-55-04-0860){ref-type="fig"}). The GSEA of *FTL* indicated that it is involved in \'ncRNA metabolic process\', \'mitochondrial translation\', \'amide biosynthetic process\', \'ncRNA processing\', \'RRNA metabolic process\', \'cytosolic part\', \'structural of constituent of ribosome\', \'RRNA binding\', \'ribosome\', \'proteasome\' and \'oxidative phosphorylation\' ([Fig. 9](#f9-ijo-55-04-0860){ref-type="fig"}). The GSEA of *SFN* and *TDRD5* indicated that they are involved in regulation of cell cycle, cell cycle phase transition, \'DNA repair\', \'regulation of nuclear division\', \'cellular respiration\', \'mitochondrial translation\', \'oxidative phosphorylation\', \'respiratory chain\', \'PPAR signaling pathway\', \'Alzheimer\'s disease\', \'fatty acid metabolism\', as well as \'complement and coagulation cascades\' ([Figs. S1 and 2](#SD1-ijo-55-04-0860){ref-type="supplementary-material"}).

Nomogram, co-expression matrix, GGI and GO network
--------------------------------------------------

A nomogram was constructed using tumor stage, radical resection, HBV infection, LINC00668, FAM86C1, TDRD5, FTL, and SFN ([Fig. 10A](#f10-ijo-55-04-0860){ref-type="fig"}). Low expression of LINC00668, FAM86C1, TDRD5, FTL, and SFN had fewer points, while radical resection, without HBV infection, and a tumor stage of III and IV accounted for fewer points as well. Additionally, fewer points suggest better OS. The co-expression matrix among LINC00668 and the PCGs ([Fig. 10B](#f10-ijo-55-04-0860){ref-type="fig"}) was also constructed. Most of them were positively correlated and showed statistical significance. GGI showed the co-expression relationships among these PCGs ([Fig. 10C](#f10-ijo-55-04-0860){ref-type="fig"}). In addition, CC and MF were visualized, and complex BPs were found using 10 PCGs ([Fig. S3](#SD1-ijo-55-04-0860){ref-type="supplementary-material"}). The intracellular ferritin complex, signal peptidase complex and protein kinase C inhibitor activity were enriched in the network.

Pharmacological targets and drugs
---------------------------------

The DEGs were acquired using edgeR. Pharmacological targets and drugs were acquired from the Connectivity Map that was constructed using the DEGs. Negatively associated drugs are potential pharmacological targets toward LINC00668 ([Tables V](#tV-ijo-55-04-0860){ref-type="table"} and [SII](#SD2-ijo-55-04-0860){ref-type="supplementary-material"}). Heatmaps and volcano plots of these DEGs are presented in [Fig. S4](#SD1-ijo-55-04-0860){ref-type="supplementary-material"}, while the chemical composition and 2D structure of these seven potential target drugs are presented in [Fig. S5](#SD1-ijo-55-04-0860){ref-type="supplementary-material"}. Enrichment analysis of the DEGs was performed using DAVID. The results included \'cell division\', \'mitotic nuclear division\', \'sister chromatid cohesion\', \'cell cycle\' and \'spliceosome enrichment\'. Detailed GO terms and KEGG pathways are presented in [Tables SIII and SIV](#SD2-ijo-55-04-0860){ref-type="supplementary-material"}, respectively. The GO terms visualized by BinGO are shown in [Fig. S6](#SD1-ijo-55-04-0860){ref-type="supplementary-material"}.

Discussion
==========

In the present study, we explored lncRNA LINC00668 and its associated PCGs for their potential implications in HCC. We found that LINC00668, *FAM86C1*, *CTAG2* and *SFN* are of significance for the diagnosis of HCC. Joint-effect analysis of these genes revealed that their diagnostic significance was better when combined than alone. Then, prognostic analysis indicated that LINC00668, *FAM86C1, TDRD5*, *FTL* and *SFN* are of prognostic significance in HCC. Furthermore, joint-effect analysis of these genes indicated that their diagnostic significance was better when combined than alone. In order to find their potential molecular mechanisms, GSEA found that LINC00668 and its PCGs have various functions in \'ncRNA processing\', \'DNA repair\', \'cell division\', \'mitotic nuclear division\', \'cell cycle phase transition\', \'oxidative phosphorylation\', \'drug metabolism cytochrome P450\', and \'PPAR signaling pathway\'. A nomogram was constructed using clinical factors, and LINC00668 and its PCGs were used to predict 1, 3 and 5 year HCC OS. Afterwards, pharmacological target drugs were identified and seven drugs: Indolylheptylamine, mimosine, disopyramide, lidocaine, NU-1025, bumetanide and DQNLAOWBTJPFKL-PKZXCIMASA-N, which may serve as potential targets with respect to LINC00668 for HCC treatment, were identified.

The discovery of many lncRNAs has notably improved our understanding of the biological behavior of many complicated diseases, including tumors. Several studies have demonstrated abnormal expression of lncRNAs in tumors, which may pinpoint to the spectrum of cancer progression and predict patient prognosis ([@b32-ijo-55-04-0860],[@b33-ijo-55-04-0860]). LncRNAs and microRNAs are major constituents of the ncRNA family, and it has been revealed that microRNAs serve a pivotal role in HCC progression ([@b34-ijo-55-04-0860]). LncRNAs function as critical regulators of many biological behaviors via modulating chromatin organization, as well as regulation at the transcriptional and post-transcriptional levels ([@b35-ijo-55-04-0860],[@b36-ijo-55-04-0860]). In addition, several studies have indicated that lncRNAs function as critical factors of tumorigenesis, and that their dysregulation induces tumor initiation, tumor growth and metastasis ([@b37-ijo-55-04-0860],[@b38-ijo-55-04-0860]). Particularly in tumor cells, lncRNAs can affect the proliferation, growth, cycle progression, apoptosis and migration of transformed cancer cells ([@b39-ijo-55-04-0860],[@b40-ijo-55-04-0860]). For instance, functioning as a molecular decoy for microRNA-221-3P, lncRNA GAPLINC modulates CD44-dependent cell invasion and is associated with poor prognosis of gastric cancer ([@b41-ijo-55-04-0860]). LncRNA FAL1 has been identified as an oncogenic lncRNA, and is associated with BMI1 and suppresses p21 expression in tumors ([@b42-ijo-55-04-0860]). Activated by TGF-β, lncRNA-ATB binds to interleukin (IL)-11 mRNA, and the autocrine induction of IL-11 and triggering of the STAT3 signaling pathway promotes the invasion-metastasis cascade in HCC cell lines ([@b43-ijo-55-04-0860]). LncRNAs HULC ([@b44-ijo-55-04-0860]) and LINC00974 ([@b45-ijo-55-04-0860]) have been reported to be involved in HCC development and progression.

LncRNA LINC00668 (NR_034100.1) is a 1,751 bp lncRNA, which is located on chromosome 18p11.31 ([@b46-ijo-55-04-0860]). Our study found that LINC00668 is upregulated in HCC tumor tissues and was associated with poor prognosis, which indicates that LINC00668 functions as an oncogene in HCC. Moreover, our present findings found that LINC00668 expression can affect cell division, cell cycle, mitotic nuclear division, sister chromosome segregation and drug metabolism cytochrome P450. Therefore, we speculate that LINC00668 may function by influencing tumor progression and development. Zhao *et al* ([@b21-ijo-55-04-0860]) found that LINC00668 expression is associated with age, T stage, clinical stage, cervical lymph node metastasis, and pathological differentiation degrees. Experiments *in vitro* indicated that LINC00668 plays an important role by promoting cell proliferation, migration, and the invasion ability of TU177 and TU212 cell lines ([@b21-ijo-55-04-0860]). LINC00668 was determined to function as an oncogene, is upregulated in tumor tissue and may serve as a potential biomarker for the targeted treatment of LSCC ([@b21-ijo-55-04-0860]). In brief, we determined that LINC00668 plays a consistent role as an oncogene in tumors, and that its expression is upregulated in LSCC and HCC tumor tissues. Zhang ([@b46-ijo-55-04-0860]) also indicated that LINC00668 is upregulated in oral squamous cell carcinoma (OSCC) tissues and cell lines, and induces poor prognosis. By competitively sponging microRNA-297, LINC00668 upregulates target gene vascular endothelial growth factor A of microRNA-297 and facilitates the proliferation of OSCC cells, which demonstrates that LINC00668 plays a role in the competitive endogenous RNA network ([@b46-ijo-55-04-0860]). It was speculate that LINC00668 may serve its pivotal role via the initiation and progression of OSCC ([@b46-ijo-55-04-0860]). These studies also indicated important roles of LINC00668 in OSCC progression and prognosis. In total, our findings are consistent with that of Zhang ([@b46-ijo-55-04-0860]), in which LINC00668 is upregulated in tumor tissues and is an indicator of poor prognosis that may play important roles in tumor progression. Furthermore, its related top 10 PCGs were explored to investigate their significance in the diagnosis and prognosis of HCC. We found these genes to have distinct diagnostic and prognostic values in HCC. Of note, potential molecular mechanisms of these genes were explored as well as LINC00668, including *FAM86C1*, *FTL*, *SFN* and *TDRD5*. These potential processes included oxidative phosphorylation, preribosome, ribosome, NCRNA processing, fatty acid metabolism, complement and coagulation cascades. Subsequently, we visualized specific biological processes they were involved in.

In addition, LINC00668 has been found to be upregulated in GC tissues and functions as an independent prognosis indicator for OS ([@b22-ijo-55-04-0860]). LINC00668 plays a role in cell cycle by epigenetically silencing cyclin dependent kinase inhibitors by binding to polycomb repressive complex 2, regulating cell growth ([@b22-ijo-55-04-0860]). LINC00668 was also found to be a predictor of poor prognosis of GC, which is consistent with our present findings ([@b22-ijo-55-04-0860]). LINC00668 has been reported to be downregulated in lung adenocarcinoma but was determined to no be associated with patient prognosis or a biomarker for lung adenocarcinoma ([@b20-ijo-55-04-0860]).

LncRNAs function through their co-expressed PCGs, and accordingly LINC00668 exerts its role via its top 10 PCGs. Our study indicates that *FAM86C1*, *TDRD5*, *FTL* and *SFN* have prognostic value for HCC, while *FAM86C1, SFN*, and *CATG2* have diagnostic value for HCC. Joint-effect analysis of LINC00668 and *FAM86C1, SFN* and *CATG2* was found to have better diagnostic value than any one of these genes alone. These results indicated their potential application in HCC. However, the significance of *FAM86C1* in diseases requires further investigation. *TDRD5* has been found to bind to piwi-interacting (pi)RNA precursors and selectively enhances pachytene piRNA processing in mice; it has been speculated that it is involved in piRNA biogenesis ([@b47-ijo-55-04-0860]). Therefore, the potential values of the aforementioned genes need further investigation in other cancers. In addition, the diagnostic significance of α-fetoprotein in this dataset was also evaluated. AFP had AUC=0.613, P=0.010 (data not shown), which did not meet the criteria of candidate diagnostic biomarkers. Therefore, we concluded that some PCGs were potential diagnostic biomarkers for HCC.

*FTL*, an iron utilization gene, has been reported to be associated with OS and its low expression is linked to the poor prognosis of HCC ([@b48-ijo-55-04-0860]). Our present results of GO analysis found that *FTL* was enriched in ferric iron binding (GO:0008199). However, our results also indicated that the high expression of *FTL* was associated with poor prognosis, which in inconsistent with the results of Shang *et al* ([@b48-ijo-55-04-0860]). Specifically, Shang *et al* ([@b48-ijo-55-04-0860]) identified that the low expression of *FTL* leads to poor prognosis, on the basis of univariate analysis, whereas our results were based on a multivariate analysis. Liu *et al* ([@b49-ijo-55-04-0860]) found that *FTL* was a DEG and is upregulated in HCC, which is consistent with our the results of this study. Wang *et al* ([@b50-ijo-55-04-0860]) reported that tumor-associated antigens combined with *FTL*, *AHSG* and *KRT23* had high sensitivity and specificity, and these antigens can act as candidate biomarkers for HCC diagnosis. Given the inconsistency in the prognostic and diagnostic values of *FTL*, further investigation should be conducted to determine its role in HCC. Of note, its potential significance in diseases, especially in malignancies, should also be evaluated further. Moreover, we constructed a nomogram to predict possible risk for 1, 3- and 5-year OS. LINC00668, and prognosis-related genes, including *FAM86C1*, *FTL*, *SFN* and *TDRD5*, and clinical factors, including tumor stage, radical resection, HBV infection status, were employed in the nomogram for survival prediction at hepatectomy. According to the above findings, we concluded that this nomogram provided notable results for survival prediction in HCC. We also identified seven potential target drugs: Indolylheptylamine, mimosine, disopyramide, lidocaine, NU-1025, bumetanide and DQNLAOWBTJPFKL-PKZXCIMASA-N of LINC00668 in HCC via the Connectivity Map. The Connectivity Map database can provide a unique method of drug development through the comparison of potential chemical compounds that can be used to treat diseases, including tumors, and it has been accepted by several researchers ([@b51-ijo-55-04-0860],[@b52-ijo-55-04-0860]). Xiao *et al* ([@b53-ijo-55-04-0860]) utilized expression profile chip data and a Connectivity Map to explore the molecular mechanisms of Hirschsprung\'s disease and candidate target drugs. They found certain chemical compounds that may helpful for minimizing the damage induced by the progression of Hirschsprung\'s disease ([@b53-ijo-55-04-0860]). We further visualized specific structures of these potential target drugs for their candidate clinical application. Further investigations concerning these potential target drugs may facilitate the development of novel strategies for the treatment of HCC.

Additionally, genetic variants concerning TP53 and catenin β-1 (CTNNB1) mutations have been linked to HCC, including diagnostic significance. Our study found that TP53 mutations did not indicate diagnostic significance (AUC:0.648, data not shown), which is less than the cutoff of 0.700. However, CTNNB1 mutations suggested diagnostic significance (AUC:0.702, data not shown), which is slightly higher than the cutoff value. In addition, genes exhibiting diagnostic significance, including FAM86C1, CTAG2 and SFN, had higher AUCs than CTNNB1 (AUC=0.766, 0.725 and 0.820, respectively). These results suggested that FAM86C1, CTAG2 and SFN may have greater diagnostic value for HCC than CTNNB1 and TP53; although further investigation is required.

There are certain limitations to the present study that need to be noted. Firstly, our findings need to be validated in a larger population. Secondly, a multi-center and validation cohort are warranted in order to explore clinical significance. In addition, functional trials regarding LINC00668 and its related PCGs are warranted to verify their function in HCC.

Our present study identified that lncRNA LINC00668 is differentially expressed and upregulated in HCC tissue. It functions as an oncogene and its high expression leads to poor prognosis for HCC. Its co-expressed correlated PCGs have been determined for diagnostic, value including *FAM86C1*, *CTAG2* and *SFN*, and prognostic value, including *FAM86C1, TDRD5*, *FTL* and *SFN* for HCC. Investigation into the molecular mechanism indicated that LINC00668 affects cell division, cell cycle, mitotic nuclear division, sister chromosome segregation and drug metabolism cytochrome P450. We speculate that it serves important roles in the progression and development of HCC. Analysis of pharmacological targets revealed 7 candidate target drugs: Indolylheptylamine, mimosine, disopyramide, lidocaine, NU-1025, bumetanide and DQNLAOWBTJPFKL-PKZXCIMASA-N. Although these drugs need further validation, this study provides novel insight into potential treatment strategies for HCC. Additionally, further functional trials and validation with a larger cohort are warranted to verify the clinical value of these findings.
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![Expressions of LINC00668 and its co-expression correlated protein-coding genes. (A-J) Expressions of, LINC00668, *P2RY4*, *SPC25* (*SPCS2*), *TDRD5*, *FTL*, *SFN*, *NOC2L*, *PRDX1*, *CATG2* and *LZIC*. CTAG2, cancer/testis antigen 2; FTL, ferritin light chain; LZIC, leucine zipper and CTNNBIP1 domain containing; NOC2L, nucleolar complex associated 2 homolog; P2RY4, pyrimidineregic receptor P2Y4; PRDX1, peroxiredoxin 1; SFN, stratifin; SPCS2, signal peptidase complex subunit 2; TDRD5, tudor domain containing 5.](IJO-55-04-0860-g00){#f1-ijo-55-04-0860}

![Scatter plots of LINC00668 and its co-expression correlated protein-coding genes in tumor and non-tumor tissues. (A-K) Scatter plots of, LINC00668, *P2RY4*, *SPCS2*, *FAM86C1*, *TDRD5*, *FTL*, *SFN*, *NOC2L*, *PRDX1*, *CATG2* and *LZIC*. CTAG2, cancer/testis antigen 2; FTL, ferritin light chain; LZIC, leucine zipper and CTNNBIP1 domain containing; NOC2L, nucleolar complex associated 2 homolog; P2RY4, pyrimidineregic receptor P2Y4; PRDX1, peroxiredoxin 1; SFN, stratifin; SPCS2, signal peptidase complex subunit 2; FAM86C1, family with sequence similarity 86 member C1; TDRD5, tudor domain containing 5.](IJO-55-04-0860-g01){#f2-ijo-55-04-0860}

![Diagnostic receiver operator curves of LINC00668 and its co-expression correlated protein-coding genes. (A-K) Diagnostic ROC curves of, in order, LINC00668, *P2RY4*, *SPCS2*, *FAM86C1*, *TDRD5*, *FTL*, *SFN*, *NOC2L*, *PRDX1*, *CATG2* and *LZIC*. CTAG2, cancer/testis antigen 2; FTL, ferritin light chain; LZIC, leucine zipper and CTNNBIP1 domain containing; NOC2L, nucleolar complex associated 2 homolog; P2RY4, pyrimidineregic receptor P2Y4; PRDX1, peroxiredoxin 1; SFN, stratifin; SPCS2, signal peptidase complex subunit 2; FAM86C1, family with sequence similarity 86 member C1; TDRD5, tudor domain containing 5; 95% CI, 95% confidence interval; AUC, area under the curve; ROCs, receiver operator characteristic.](IJO-55-04-0860-g02){#f3-ijo-55-04-0860}

![Joint-effect analysis of diagnostic receiver operator curves of LINC00668 and diagnosis related genes. (A-F) Diagnostic receiver operator curves of, in order, LINC00668 and *FAM86C1*; LINC00668 and *SFN*; LINC00668 and *CTAG2*; *FAM86C1* and *SFN*; *FAM86C1* and *CTAG2*; *SFN* and *CTAG2*. CTAG2, cancer/testis antigen 2; FAM86C1, family with sequence similarity 86 member C1; SFN, stratifin; 95% CI, 95% confidence interval; AUC, area under the curve.](IJO-55-04-0860-g03){#f4-ijo-55-04-0860}

![Kaplan-Meier plots of LINC00668 and its co-expression correlated protein-coding genes. (A-K) Kaplan-Meier plots of, LINC00668, *P2RY4*, *SPCS2*, *FAM86C1*, *TDRD5*, *FTL*, *SFN*, *NOC2L*, *PRDX1*, *CATG2* and *LZIC*. CTAG2, cancer/testis antigen 2; FTL, ferritin light chain; LZIC, leucine zipper and CTNNBIP1 domain containing; NOC2L, nucleolar complex associated 2 homolog; P2RY4, pyrimidineregic receptor P2Y4; PRDX1, peroxiredoxin 1; SFN, stratifin; SPCS2, signal peptidase complex subunit 2; FAM86C1, family with sequence similarity 86 member C1; TDRD5, tudor domain containing 5.](IJO-55-04-0860-g04){#f5-ijo-55-04-0860}

![Joint-effect analysis of Kaplan-Meier plots of LINC00668 and diagnosis-related genes. (A-J) Kaplan-Meier plots of LINC00668 and *FAM86C1*; LINC00668 and *TDRD5*; LINC00668 and *FTL*; LINC00668 and *SFN*; *FAM86C1* and *TDRD5*; *FAM86C1* and *FTL*; *FAM86C1* and *SFN*; *TDRD5* and *FTL*; *TDRD5* and *SFN*; and *FTL* and *SFN*. FTL, ferritin light chain; FAM86C1, family with sequence similarity 86 member C1; SFN, stratifin; TDRD5, tudor domain containing 5.](IJO-55-04-0860-g05){#f6-ijo-55-04-0860}

![Gene Set Enrichment Analysis of LINC00668 using GO and KEGG pathways. (A-I) Gene ontology results of LINC00668; (J-L) KEGG pathway results of LINC00668. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, false discovery rate; NES, normalized enrichment score.](IJO-55-04-0860-g06){#f7-ijo-55-04-0860}

![Gene Set Enrichment Analysis of *FAM86C1* using GO and KEGG pathways. (A-I) Gene ontology results of *FAM86C1*; (J-L) KEGG pathway results of *FAM86C1*. FAM86C1, family with sequence similarity 86 member C1; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, false discovery rate; NES, normalized enrichment score.](IJO-55-04-0860-g07){#f8-ijo-55-04-0860}

![Gene Set Enrichment Analysis of *FTL* using GO and KEGG pathways. (A-I) Gene ontology results of *FTL*; (J-L) KEGG pathway results of *FTL*. FTL, ferritin light chain; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, false discovery rate; NES, normalized enrichment score.](IJO-55-04-0860-g08){#f9-ijo-55-04-0860}

###### 

Nomogram, co-expression matrix and gene-gene interaction network of LINC00668 and protein-coding genes. (A) Nomogram constructed using LINC00668, *FAM86C1, TDRD5, FTL, SFN*, tumor stage, radical resection and HBV infection status; (B) Co-expression matrix of LINC00668 and its protein-coding genes; blue and red indicate positive and negative correlation, respectively. ^\*^, ^\*\*^, and ^\*\*\*^ denote P≤0.05, 0.01, and 0.001, respectively. (C) Co-expression network of gene-gene interactions of LINC00668 and its protein-coding genes. HBV, hepatitis B virus; FTL, ferritin light chain; FAM86C1, family with sequence similarity 86 member C1; SFN, stratifin; TDRD5, tudor domain containing 5.

![](IJO-55-04-0860-g09)

![](IJO-55-04-0860-g10)

###### 

Top 10 PCGs associated with LINC00668.

  LncRNA      PCG         Coefficient   P-value    95% CI
  ----------- ----------- ------------- ---------- -----------
  LINC00668   *P2RY4*     0.46          1.30E-20   0.37-0.54
  LINC00668   *SPCS2*     0.4           6.54E-16   0.31-0.49
  LINC00668   *FAM86C1*   0.39          1.20E-14   0.30-0.47
  LINC00668   *TDRD5*     0.38          1.98E-14   0.29-0.47
  LINC00668   *FTL*       0.38          3.16E-14   0.29-0.46
  LINC00668   *SFN*       0.37          9.85E-14   0.28-0.46
  LINC00668   *NOC2L*     0.37          3.84E-13   0.27-0.45
  LINC00668   *PRDX1*     0.36          1.01E-12   0.27-0.45
  LINC00668   *CTAG2*     0.36          1.46E-12   0.26-0.44
  LINC00668   *LZIC*      0.36          1.54E-12   0.26-0.44

PCG, protein-coding gene; CI, confidence interval; CTAG2, cancer/testis antigen 2; FAM86C1, family with sequence similarity 86 member C1; FTL, ferritin light chain; LZIC, leucine zipper and CTNNBIP1 domain containing; NOC2L, nucleolar complex associated 2 homolog; P2RY4, pyrimidineregic receptor P2Y4; PRDX1, peroxiredoxin 1; SFN, stratifin; SPCS2, signal peptidase complex subunit 2; TDRD5, tudor domain containing 5.

###### 

Demographic characteristics of patients with hepatocellular carcinoma in The Cancer Genome Atlas database.

  Variables                                                            Patients (n=370)   Overall survival                                     
  -------------------------------------------------------------------- ------------------ ------------------ ------- ------------------------- -------------
  Gender                                                                                                                                       0.262
   Female                                                              121                51                 1,490   Ref.                      
   Male                                                                249                79                 2,486   0.817 (0.573-1.164)       
  Age (years)                                                                                                                                  0.217
   ≤60                                                                 177                55                 2,532   Ref.                      
   \>60                                                                193                75                 1,622   1.246 (0.879-1.766)       
  Child-pugh[a](#tfn2-ijo-55-04-0860){ref-type="table-fn"}                                                                                     0.184
   A                                                                   216                59                 2,542   Ref.                      
   B + C                                                               22                 9                  1,005   1.614 (0.796-3.270)       
  HBV infection[b](#tfn3-ijo-55-04-0860){ref-type="table-fn"}                                                                                  **\<0.001**
   No                                                                  247                104                1,210   Ref.                      
   Yes                                                                 104                20                 NA      **0.357 (0.221-0.578)**   
  HCV infection[c](#tfn4-ijo-55-04-0860){ref-type="table-fn"}                                                                                  0.730
   No                                                                  295                105                1,791   Ref.                      
   Yes                                                                 56                 19                 1,229   1.090 (0.667-1.782)       
  Histologic grade[d](#tfn5-ijo-55-04-0860){ref-type="table-fn"}                                                                               0.750
   G1                                                                  55                 18                 2,116   Ref.                      
   G2                                                                  177                60                 1,685   1.181 (0.697-2.000)       0.537
   G3                                                                  121                43                 1,622   1.233 (0.711-2.140)       0.456
   G4                                                                  12                 5                  NA      1.693 (0.626-4.584)       0.300
  Tumor stage[e](#tfn6-ijo-55-04-0860){ref-type="table-fn"}                                                                                    **\<0.001**
   I                                                                   171                42                 2,532   Ref.                      
   II                                                                  85                 26                 1,852   1.427 (0.874-2.330)       0.155
   III + IV                                                            90                 48                 770     **2.764 (1.823-4.190)**   **\<0.001**
  Ishak fibrosis score[f](#tfn7-ijo-55-04-0860){ref-type="table-fn"}                                                                           0.874
   0                                                                   74                 30                 2,131   Ref.                      
   1,2                                                                 31                 9                  1,372   0.917 (0.429-1.962)       0.823
   3,4                                                                 28                 6                  NA      0.682 (0.281-1.654)       0.397
   5                                                                   9                  2                  1,386   0.750 (0.177-3.167)       0.695
   6                                                                   69                 17                 NA      0.766 (0.418-1.403)       0.388
  AFP (ng/ml)[g](#tfn8-ijo-55-04-0860){ref-type="table-fn"}                                                                                    0.832
   ≤400                                                                213                62                 2,456   Ref.                      
   \>400                                                               64                 22                 2,486   1.055 (0.645-1.724)       
  Radical resection[h](#tfn9-ijo-55-04-0860){ref-type="table-fn"}                                                                              **0.007**
   R0                                                                  323                110                1,875   Ref.                      
   R1 + R2 + RX                                                        40                 17                 837     **2.030 (1.213-3.395)**   
  Vascular invasion[i](#tfn10-ijo-55-04-0860){ref-type="table-fn"}                                                                             0.155
   No                                                                  206                60                 2,131   Ref.                      
   Yes                                                                 108                36                 2,486   1.351 (0.892-2.047)       
  Alcohol history[j](#tfn11-ijo-55-04-0860){ref-type="table-fn"}                                                                               0.896
   No                                                                  234                                           Ref.                      
   Yes                                                                 117                                           1.026 (0.703-1.496)       

132 patients data were missing;

19 patients data were missing;

19 patients data were missing;

5 patients data were missing;

14 patients data were missing;

159 patients data were missing;

93 patients data were missing;

7 patients data were missing;

56 patients data were missing;

19 patients data were missing. Bold indicates significant P-values. HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, α-fetoprotein; MST, median survival time; HR, hazard ratio; 95% CI, 95% confidence interval; Ref., Reference.

###### 

Prognostic analysis of *LINC00668* and genes for overall survival in The Cancer Genome Atlas database.

  Variables          Patients (n=370)   Overall survival                                                                           
  ------------------ ------------------ ------------------ ------- ------------------------- ----------- ------------------------- -----------
  LINC00668                                                                                  **0.025**                             **0.029**
   Low expression    185                58                 1,852   Ref.                                  Ref.                      
   High expression   185                72                 1,397   **1.486 (1.051-2.102)**               **1.540 (1.044-2.270)**   
  *P2RY4*                                                                                    0.865                                 0.646
   Low expression    185                65                 1,694   Ref.                                  Ref.                      
   High expression   185                65                 1,624   1.031 (0.729-1.457)                   0.914 (0.622-1.343)       
  *SPCS2*                                                                                    0.362                                 0.884
   Low expression    185                70                 1,694   Ref.                                  Ref.                      
   High expression   185                60                 1,685   0.851 (0.602-1.203)                   0.971 (0.659-1.433)       
  *FAM86C1*                                                                                  **0.001**                             **0.003**
   Low expression    185                54                 2,456   Ref.                                  Ref.                      
   High expression   185                76                 1,088   **1.796 (1.266-2.550)**               **1.853 (1.241-2.768)**   
  *TDRD5*                                                                                    **0.007**                             **0.012**
   Low expression    185                59                 2,116   Ref.                                  Ref.                      
   High expression   185                71                 1,372   **1.624 (1.142-2.308)**               **1.680 (1.123-2.514)**   
  *FTL*                                                                                      0.218                                 **0.042**
   Low expression    185                64                 1,791   Ref.                                  Ref.                      
   High expression   185                66                 1,685   1.242 (0.880-1.754)                   **1.499 (1.015-2.214)**   
  *SFN*                                                                                      **0.003**                             **0.005**
   Low expression    185                54                 2,131   Ref.                                  Ref.                      
   High expression   185                76                 1,372   **1.706 (1.201-2.421)**               **1.777 (1.194-2.646)**   
  *NOC2L*                                                                                    0.408                                 0.996
   Low expression    185                64                 1,791   Ref.                                  Ref.                      
   High expression   185                66                 1,560   1.157 (0.819-1.633)                   0.999 (0.677-1.473)       
  *PRDX1*                                                                                    0.172                                 0.160
   Low expression    185                62                 1,685   Ref.                                  Ref.                      
   High expression   185                68                 1,694   1.272 (0.901-1.795)                   1.318 (0.897-1.936)       
  *CTAG2*                                                                                    0.078                                 0.283
   Low expression    185                59                 2,131   Ref.                                  Ref.                      
   High expression   185                71                 1,397   1.366 (0.966-1.931)                   1.235 (0.840-1.816)       
  *LZ*IC                                                                                     0.990                                 0.898
   Low expression    185                64                 1685    Ref.                                  Ref.                      
   High expression   185                66                 1694    0.998 (0.706-1.410)                   0.975 (0.662-1.435)       

P-values were adjusted for radical resection, tumor stage and HBV infection; bold indicates significant P-values. NA, not available; MST, median survival time; HR, hazard ratio; 95% CI, 95% confidence interval; Ref., Reference; CTAG2, cancer/testis antigen 2; FTL, ferritin light chain; LZIC, leucine zipper and CTNNBIP1 domain containing; NOC2L, nucleolar complex associated 2 homolog; P2RY4, pyrimidineregic receptor P2Y4; PRDX1, peroxiredoxin 1; SFN, stratifin; SPCS2, signal peptidase complex subunit 2; FAM86C1, family with sequence similarity 86 member C1; TDRD5, tudor domain containing 5.

###### 

Joint-effect analysis of *LINC00668* and genes for overall survival.

  Group    *LINC00668* expression   *FAM86C1*   *TDRD5*   *FTL*   *SFN*   Overall survival                                    
  -------- ------------------------ ----------- --------- ------- ------- ------------------ ------ ------------------------- --------------
  A        Low                      Low                                   26/97              2456   Ref.                      **\<0.001**
  B        Low                      High                                  60/176             1624   **1.604 (0.946-2.721)**   0.080
           High                     Low                                                                                       
  C        High                     High                                  44/97              899    **2.861 (1.618-5.058)**   **\<0.001**
  a        Low                                  Low                       27/110             3258   Ref.                      **0.004**
  b        Low                                  High                      63/150             1560   **2.190 (1.314-3.649)**   **0.003**
           High                                 Low                                                                           
  c        High                                 High                      40/110             1372   **2.380 (1.350-4.196)**   **0.003**
  ①        Low                                            Low             29/91              1791   Ref.                      **0.005**
  ②        Low                                            High            64/188             1852   1.297 (0.785-2.142)       0.310
           High                                           Low                                                                 
  ③        High                                           High            37/91              1229   **2.350 (1.356-4.073)**   **0.002**
  1        Low                                                    Low     31/107             2456   Ref.                      **0.006**
  2        Low                                                    High    50/156             2116   1.512 (0.908-2.518)       0.112
           High                                                   Low                                                         
  3        High                                                   High    49/107             1229   **2.284 (1.370-3.806)**   **0.002**
  i                                 Low         Low                       24/94              NA     Ref.                      **\<0.001**
  ii                                Low         High                      65/182             1852   1.691 (0.996-2.873)       0.052
                                    High        Low                                                                           
  iii                               High        High                      41/94              837    **3.415 (1.882-6.195)**   **\<0.0001**
  I                                 Low                   Low             33/107             2456   Ref.                      **0.003**
  II                                Low                   High            52/156             1624   1.351 (0.823-2.216)       0.234
                                    High                  Low                                                                 
  III                               High                  High            45/107             931    **2.321 (1.399-3.851)**   **0.001**
  \*                                Low                           Low     26/105             2456   Ref.                      **\<0.001**
  \*\*                              Low                           High    56/160             1624   **1.814 (1.068-3.079)**   **0.027**
                                    High                          Low                                                         
  \*\*\*                            High                          High    48/105             837    **2.856 (1.662-4.910)**   **\<0.001**
  ▪                                             Low       Low             35/97              2116   Ref.                      **\<0.001**
  ▪▪                                            Low       High            53/176             2456   1.127 (0.684-1.857)       0.640
                                                High      Low                                                                 
  ▪▪▪                                           High      High            42/97              1271   **2.613 (1.508-4.525)**   **\<0.001**
  §                                             Low               Low     27/109             3125   Ref.                      **0.002**
  §§                                            Low               High    59/152             1423   **2.093 (1.253-3.495)**   **0.005**
                                                High              Low                                                         
  §§§                                           High              High    44/109             1271   **2.683 (1.534-4.693)**   **\<0.001**
  &                                                       Low     Low     32/100             2116   Ref.                      **\<0.001**
  &&                                                      Low     High    54/170             1852   **1.031 (0.627-1.694)**   **0.904**
                                                          High    Low                                                         
  &&&                                                     High    High    44/100             931    **2.445 (1.461-4.092)**   **\<0.001**

P-values were adjusted for radical resection, tumor stage and HBV infection; bold indicates significant P-values. NA, not available; MST, median survival time; HR, hazard ratio; 95% CI, 95% confidence interval; Ref., Reference; FAM86C1, family with sequence similarity 86 member C1; FTL, ferritin light chain; SFN, stratifin; TDRD5, tudor domain containing 5.

###### 

Pharmacological target and drug.

  Drug                          PubChem CID   Mean     Enrichment   P-value
  ----------------------------- ------------- -------- ------------ ---------
  Indolylheptylamine            35874         −0.82    −0.974       0.00139
  Mimosine                      3862          −0.47    −0.900       0.00188
  Disopyramide                  3114          −0.375   −0.794       0.00358
  Lidocaine                     3676          −0.441   −0.720       0.00374
  NU-1025                       135398517     −0.585   −0.947       0.00622
  Bumetanide                    2471          −0.39    −0.692       0.01930
  DQNLAOWBTJPFKL-PKZXCIMASA-N   5279552       −0.436   −0.900       0.02014
